金融界消息 截至2025年5月21日收盘，ST浩丰（300419）报收于5.39元，上涨3.26%，换手率3.74%，成 交量13.75万手，成交金额7397.04万元。 通过天眼查大数据分析，北京浩丰创源科技股份有限公司共对外投资了15家企业，参与招投标项目422 次，知识产权方面有商标信息15条，专利信息1条，此外企业还拥有行政许可5个。 来源：金融界 ST浩丰最新一期业绩显示，截至2025一季报，公司营业总收入4543.51万元、同比减少20.58%，归属净 利润503.24万元，同比减少40.85%，扣非净利润518.45万元，同比减少32.84%，流动比率1.719、速动比 率1.498、资产负债率36.64%。 天眼查商业履历信息显示，北京浩丰创源科技股份有限公司，成立于2005年，位于北京市，是一家以从 事科技推广和应用服务业为主的企业。企业注册资本36775.377万人民币，实缴资本36775.377万人民 币。公司法定代表人为王剑。 资金流向方面，今日主力资金净流入1730.53万元，占比成交额23.39%。其中，超大单净流入548.45万 元、占成交额7.41%，大单净流入1182.08万 ...

Financial Performance - The group's revenue from continuing operations for the year ended December 31, 2024, was HKD 1.018 billion, a decrease of 24% compared to the previous year[12]. - The main revenue source, the digital operation service "Yizhi Nuo," generated HKD 869 million, down 8% year-on-year, due to changes in business and client structures driven by medical reform policies[12]. - The "Mango Health" platform recorded revenue of HKD 146 million, a significant decline of 63%, primarily due to restructuring efforts that divested loss-making segments[12]. - The company reported a loss of approximately HKD 177.19 million for the year, an increase of 41% compared to HKD 125.35 million in the previous year[13]. - Financing costs rose to approximately HKD 17.61 million, up from HKD 3.61 million in the previous year, primarily due to interest expenses from convertible bonds issued in March 2024[13]. - The revenue for the year ended December 31, 2024, was HKD 869,555,000, a decrease of 8% compared to HKD 943,936,000 in 2023[28]. - The gross profit margin for 2024 was 38.7%, down from 40.7% in 2023, reflecting a slight decline of 2.0%[28]. - The loss from continuing operations for the year was HKD 177,190,000, an increase of 48% compared to HKD 119,567,000 in 2023[48]. - The adjusted loss from continuing operations was HKD 103,235,000, a slight improvement of 3% from HKD 106,466,000 in 2023[48]. Business Strategy and Development - The company is focusing on developing high-quality clients and enhancing the core competitiveness of its digital operation services[9]. - The board plans to implement specific development directions for international culture, media, and entertainment businesses to realize the group's vision[10]. - The company is exploring opportunities in the rapidly evolving global culture, entertainment, and media markets, driven by technological innovations and changing consumer habits[8]. - The company aims to build a global content creation platform, focusing on international culture, media, and entertainment business development[13]. - The company is committed to optimizing its digital operation services and smart health service platforms while integrating resources for global market expansion[7]. - The company has successfully entered the second phase of its business model with the launch of the "Ciyuan Platform," providing comprehensive digital transformation services for pharmaceutical companies[18]. - The company initiated an AI Smart Laboratory project in 2024, enhancing the efficiency and quality of medical services through interactive and personalized solutions[19]. - The company aims to enhance its supply chain sustainability by regularly evaluating supplier compliance and performance[45]. Corporate Governance - The board of directors consists of seven members, responsible for setting company policies, business goals, and monitoring financial performance[73]. - The board held a total of six meetings during the reporting period, with all members actively participating[75]. - The corporate governance committee held one meeting to review training and development for directors and senior management, as well as compliance with governance codes[80]. - The nomination committee conducted two meetings to assess board structure and diversity, reaffirming commitment to gender diversity[82]. - The remuneration committee is responsible for establishing a transparent remuneration policy for all directors and senior management[83]. - The company has complied with the corporate governance code, except for a temporary non-compliance regarding the separation of roles between the chairman and CEO[72]. - The company has established various committees, including the executive, governance, nomination, remuneration, and audit committees, to ensure effective governance[77]. - The board consists of seven directors as of December 31, 2024, including two women, representing 28.6% gender balance[88]. Environmental, Social, and Governance (ESG) Initiatives - The ESG report for the year 2024 aims to objectively disclose the group's compliance status and performance in environmental, social, and governance aspects[123]. - The report adheres to the principles of materiality, quantification, balance, and consistency to ensure accuracy and reliability[125]. - The group has established an ESG framework led by the board, focusing on sustainable development strategies and enhancing risk management capabilities[127]. - A dedicated ESG working group has been set up to oversee the implementation of sustainability strategies and ensure compliance with regulatory requirements[128]. - The group identified 19 significant ESG issues impacting operations, emphasizing the importance of stakeholder engagement in shaping its sustainability strategy[131]. - The group has implemented strict supplier evaluation standards to ensure the quality and safety of products, adhering to relevant laws and regulations[137]. - The group has established a quality management team to oversee product information and ensure compliance with quality standards, achieving ISO 9001:2015 certification[138]. - The group has developed a comprehensive response plan for handling customer complaints and emergencies, ensuring effective management of incidents[139]. Employee and Workplace Policies - The employee turnover rate is 27.54%, with a higher rate of 31.45% for male employees and 27.93% for those in mainland China[148]. - The group has implemented strict compliance measures, including signing compliance commitment letters for new employees[145]. - The group has conducted anti-corruption training for all board members and employees to enhance awareness[146]. - The group has a total of 221 full-time employees, with 109 males and 112 females[148]. - The average training hours for male employees is 3.79 hours, while for female employees it is 6.11 hours, with 100% participation in training across all categories[153]. - Senior management received an average of 11.43 training hours, while middle management received 4.76 hours, and regular employees received 4.44 hours, all with 100% participation[153]. Financial Position and Ratios - The current ratio improved from 0.72 on December 31, 2023, to 1.02 on December 31, 2024, indicating better liquidity[63]. - The debt-to-equity ratio as of December 31, 2024, was 4.9 times, a significant increase from 27.21% in 2023, primarily due to the issuance of convertible bonds amounting to HKD 120,000,000[64]. - The total bank and other borrowings amounted to approximately HKD 75,051,000 as of December 31, 2024, compared to HKD 72,231,000 in 2023[66]. - The group had a net foreign exchange loss of approximately HKD 1,879,000 during the year, compared to HKD 1,508,000 in the previous year, due to fluctuations in the Chinese Yuan and Korean Won against the Hong Kong Dollar[65]. Community Engagement and Social Responsibility - The company aims to increase community investment and promote industry collaboration and social responsibility practices to support the construction of a healthy China[175]. - The company plans to donate consultation cards to promote healthcare resources to grassroots levels, enhancing accessibility and fairness in medical services[175]. - The company is committed to corporate social responsibility, focusing on supporting local community development through job creation[46].

于股权转让协议完成后，獴哥集团成员公司将成为该公司的全资附属公司，且不再存有任何合约安排， 而獴哥集团的财务业绩将继续并入该集团财务报表。 根据股权转让协议，该集团能够按名义对价取得獴哥集团少数股东所持部分股权的所有权，令公司全资 拥有獴哥集团(连同其营运业务)。如此精简獴哥集团的企业架构将令集团自主且全面掌控獴哥集团及獴 哥健康业务的未来企业与业务发展，并悉数享有其所产生的经济效益。 智通财经APP讯，弘毅文化集团(00419)公布，就獴哥健康业务而言，獴哥集团已剥离其疫苗和体检业 务，终止其私域电商业务，并专注于运营健康消费业务， 而VIE 合约安排项下 的VIE 结构将不再属必 要。 公司已于2025年4月1日与ESOP及自然人SPV订立合资平台(即Meerkat Health Holdings Limited)股权转让 文件，旨在收购彼等合共持有合资平台的40%股权，令合资平台及其附属公司成为该集团的全资附属公 司。同日，WFOE与中国股权拥有人分别订立OPCO股权转让协议A及OPCO股权转让协议B，供彼等向 WFOE转让各自于OPCO持有的60%及40%股权;WFOE及OPCO亦就终止VIE合约安排 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部或任何部份內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 Hony Media Group 弘 毅 文 化 集 團 （ 於開曼群島註冊成立之有限公司） （股份代號：419） 中期業績公佈 華誼騰訊娛樂有限公司（「本公司」）董事會（「董事會」）欣然提呈本公司及其附屬公司（「本集 團」）截至二零二四年六月三十日止六個月之簡明綜合中期業績，連同二零二三年同期之比 較數字。簡明綜合中期業績已經由本公司審核委員會審閱。 簡明綜合中期收益表 截至二零二四年六月三十日止六個月 截至六月三十日止六個月 | --- | --- | |--------------------------------------------|--------------------------------------------------| | | | | 二零二 四 年 | 二 零 二三 年 | | （ 未 經 審 核 ） （ | 未 經 審 核 ） （ 經 重 列 ） （ 附 註 26 ） ...

. 就診 者 — 透過 微 信小 程 式「 醫 智 諾就 醫 助手 」可 以輕 鬆 找 到醫生、線上覆診及諮詢、訂購處方藥等 . 第 一 階 段 ： 透 過 為 藥 企 提 供 場 景 化 的 數 字 化 運 營 解 決 方 案 ， 醫 智 諾 致 力 於 協 助 藥 企 實 現 線 下 與 線 上 的 一 體 化 數 字 轉 型 的 初 步 階 段 。 此 階 段 主 要 收 入 來 自 為 藥 企 提 供 數 字 化 營 銷 系 統 、 市 場 推 廣 服 務 、 臨 床 科 研 服 務 和 O2O 數 位 運 營 服 務 等 方 面 ， 同 時 收 取 藥 企 的 資 訊 服 務 費 、 技 術 服務費和推廣服務費。 括 透 過 向 藥 企 全 產 業 鏈 提 供 不 同 的 賦 能 ， 基 於 效 率 促 進 從而收取的賦能服務費。 | --- | --- | --- | |-------------------------------|--------------------------------------|------------------------------------------| ...

Financial Performance - Total revenue for the year ended December 31, 2022, was HKD 1,344,031, a decrease from HKD 1,581,391 in 2021, representing a decline of approximately 15%[6] - The company recorded a pre-tax loss of HKD 65,762 for the year, compared to HKD 90,057 in the previous year[9] - The company reported a post-tax loss of HKD 13,432,000 for the year ended December 31, 2023, compared to a loss of HKD 14,340,000 in 2022[33] - The group's total loss for the year significantly narrowed to HKD 125,354,000, a decrease of over 60% from HKD 316,598,000 in 2022, aided by a reduction in losses from the "Yizhi Nuo" and "Mongoose Health" businesses[141] - Revenue for the period from January 1, 2023, to October 5, 2023, was HKD 92,271,000, with a gross profit of HKD 43,028,000[131] Assets and Liabilities - The company reported a total asset value of HKD 589,186 as of December 31, 2022, with total liabilities amounting to HKD 239,261[5] - The company reported a total of HKD 277,493 in non-current assets as of December 31, 2022[6] - The company’s total liabilities decreased to HKD 105,165,000 in 2023 from HKD 194,610,000 in 2022[24] - The company’s total liabilities, including bank and other borrowings, were approximately HKD 72,231,000 as of December 31, 2023[81] - The total current liabilities decreased from HKD 87,187,000 in 2022 to HKD 79,675,000 in 2023, representing a reduction of approximately 8.7%[108] Cash Flow and Financing - Cash and cash equivalents as of December 31, 2023, amounted to HKD 23,131,000, a decrease from HKD 65,980,000 in 2022[24] - The company repaid all bank borrowings amounting to HKD 5,605,000 during the year ended December 31, 2023, with interest rates decreasing from 4.35% in 2022 to 3.45% in 2023[65] - The company has signed a subscription agreement for a convertible bond of HKD 120 million with Hongyi Investment, aimed at supporting core business development[136] - The company is actively expanding financing channels to lay a foundation for future growth[136] Business Operations and Strategy - The company completed the acquisition of a 21.88% stake in Deep Sea Health Limited for RMB 20 million, gaining indirect ownership of a high-end clinic and hospital business in Shanghai[28] - The company has terminated the operation of the "Health and Wellness Services - Beihu No. 9 Club," classifying it as a discontinued operation[106] - The company has terminated the operation of the "Beihu No. 9 Club" following the early termination of the lease agreement[130] - The group is focusing on optimizing resource allocation by gradually divesting non-core businesses[140] - The group aims to ensure product and service quality from the source by implementing strict supplier admission standards[200] Market and Industry Insights - The compound annual growth rate (CAGR) for revenue in the medical industry segment is projected at 28.91% over the next five years[21] - The global digital healthcare market is projected to reach USD 286.35 billion in 2023 and USD 365.67 billion in 2024, indicating significant market potential[134] - The Chinese internet healthcare market is projected to reach RMB 200 billion by 2026, indicating significant growth potential[162] - The digital healthcare market is expected to benefit from post-pandemic changes in healthcare models and ongoing improvements in medical insurance policies[162] Digital Transformation and Innovation - The "ECN Yuan Zhi Digital Human" solution was launched to enhance productivity in the medical field, allowing for the rapid creation of AI digital avatars from just a few minutes of effective audio-visual material from doctors[144] - The strategic cooperation agreement with Tencent Cloud aims to promote digital transformation in the medical industry, focusing on AI technology development and joint product development[143] - The company is actively expanding its digital health service platform, focusing on providing integrated digital transformation solutions for pharmaceutical enterprises[186] - The company aims to enhance the accessibility of pharmaceuticals and improve patient quality of life through its digital operational solutions[186] Shareholder and Equity Information - The company issued 15,000,000 shares under the share incentive plan in 2023, a decrease from 77,500,000 shares in 2022[94] - The company has a total of 150,000,000,000 ordinary shares with a par value of HKD 0.02 as of December 31, 2023[112] - The company’s total issued shares increased from 13,498,107,000 in 2022 to 13,585,339,000 in 2023, reflecting an increase of approximately 0.65%[112] Research and Development - The company has initiated collaborations with universities to establish the "Yizhi Nuo Research Institute" to promote medical research and social welfare[191] - The company plans to leverage AI technology to enhance its operational systems and maintain industry leadership[161] Operational Efficiency - The company has eliminated high-cost and uncertain growth areas such as vaccination and health check services to enhance operational efficiency[194] - The company recognized share-based compensation expenses of approximately HKD 2,845,000 for the year ended December 31, 2023, a significant decrease from HKD 17,541,000 in 2022[117]

Share Grants and Vesting - As of December 31, 2022, the company granted a total of 77,500,000 incentive shares to employees, with 15,000,000 shares expiring during the year[3] - A total of 62,500,000 shares were vested and will be released in four equal installments of 25% each year from 2023 to 2026[3] - The total number of shares granted under the stock option and incentive plans represents approximately 0.46% of the weighted average number of shares issued during the year[8]

中期報告 2023 1 華 誼 騰 訊 娛 樂 有 限 公 司 二 零 二 三 年 中 期 報 告 2 零一二年以來的數字經濟年均增速高達15.9%， 管理層討論及分析 華 誼 騰 訊 娛 樂 有 限 公 司 3 二 零 二 三 年 中 期 報 告 . 醫 生 — 提 供 全 鏈 路 閉 環 線 上 診 療 服 務 場 景，包括就診者管理、電子處方等 目 前 醫 智 諾 的 發 展 重 點 放 在 服 務 醫 藥 企 業 ， 以 「 藥 企 帶 動 全 產 業 鏈 」為 策 略 ， 利 用 上 述 場 景 化 的 醫 療 服 務 平 台 技 術 賦 能 企 業 ， 建 設 基 於 醫 智 諾 數 字 化 生 態 上 的 醫 療 行 業 全 產 業 鏈 數 字 化 運 營。 截 至 二 零 二 三 年 六 月 三 十 日 ， 已 與 醫 智 諾 平 台 簽約的藥廠數目增至195家，較二零二二年底增 加 22% ， 其 中 包 括 國 內 大 型 藥 企 如 齊 魯 藥 業 、 江 蘇 恒 瑞 藥 業 、 石 藥 集 團 、 安 徽 藥 業 等 ； 另 一 方 面 醫 智 諾 平 台 目 前 已 覆 蓋 31,9 ...

Financial Performance - Yizhi Nuo's revenue for the first half of 2023 was HKD 482,276,000, representing a 110% increase compared to HKD 229,124,000 in the same period of 2022[3]. - Total revenue for the six months ended June 30, 2023, was HKD 687,662,000, representing a 2% increase from HKD 672,683,000 in the same period of 2022[82]. - The company reported a net loss of HKD 57,377,000 for the six months ended June 30, 2023, compared to a net loss of HKD 141,081,000 in the same period of 2022[86]. - For the six months ended June 30, 2023, the company reported a loss of approximately HKD 54,141,000, a 56% reduction compared to a loss of HKD 122,995,000 in the same period of 2022[59]. - The company reported a net loss attributable to equity holders of HKD 118,413,000 for the period, with a significant increase in marketing and promotional expenses to HKD 197,005,000[175]. Revenue Breakdown - Revenue from the medical industry digital operation services reached HKD 482,276,000, a significant increase of 110% compared to HKD 229,124,000 in the previous year[82]. - Revenue from the "Smart Health Service Platform" decreased by 57% to approximately HKD 147,591,000, accounting for 21% of the group's total revenue, down from 51% in 2022[67]. - Revenue from the health and wellness service "Beihu No. 9 Club" increased by 9% year-on-year, reaching HKD 57,000,000 following the lifting of pandemic restrictions[52]. - The entertainment and media segment generated revenue of HKD 375,000, a significant decrease from HKD 44,958,000 in the same period last year[165]. - The healthcare service segment reported revenue of HKD 11,574,000, up from HKD 5,390,000 in the previous year, marking an increase of 115%[165]. Profitability and Margins - The gross profit for Yizhi Nuo was HKD 198,315,000, up 59% from HKD 124,557,000 year-on-year[3]. - The gross margin for the company's health and wellness business improved significantly to 9.8%, compared to 1.5% in 2022[23]. - Gross profit for the same period was approximately HKD 239,875,000, representing a 71% increase from HKD 140,528,000 year-on-year, with a gross margin improvement to 35% from 21%[37]. - The gross profit margin for the medical digital operation services increased to 35%, up from 21% in the previous year[73]. Expenses and Costs - Marketing and sales expenses increased by 22% to approximately HKD 218,477,000, primarily due to the Yizhi Nuo business[24]. - The cost of sales for the six months ended June 30, 2023, was approximately HKD 447,787,000, a decrease of 16% compared to HKD 532,155,000 in the previous year[37]. - The company incurred costs of HKD 283,961,000 related to Medical Industry Digital Operations during the period, reflecting a substantial increase from HKD 104,567,000 in the previous year[175]. Assets and Liabilities - As of June 30, 2023, the group reported a net current asset of HKD 16,182,000, maintaining a current ratio of 1.07, indicating a stable liquidity position[28]. - The total liabilities as of June 30, 2023, amounted to HKD 281,122,000, compared to HKD 239,261,000 at the end of December 2022[79]. - The company’s total equity decreased to HKD 287,354,000 as of June 30, 2023, from HKD 349,925,000 at the end of December 2022[79]. - Total assets decreased to HKD 568,476,000 as of June 30, 2023, from HKD 589,186,000 at the end of 2022[134]. Strategic Initiatives - The company plans to expand its private domain e-commerce business to meet diverse consumer needs, leveraging its existing healthcare services[7]. - The company aims to create a dual-driven model by integrating healthcare and lifestyle businesses to generate more value for the group[14]. - The company plans to continue expanding its digital healthcare services and smart health service platform to capture more market share in the healthcare industry[156]. Market Position and Growth - As of June 30, 2023, the number of pharmaceutical companies signed with the Yizhi Nuo platform increased to 195, a 22% increase from the end of 2022[2]. - The number of registered doctors on the Yizhi Nuo platform grew by 24% to 31,935 as of June 30, 2023, compared to 25,819 at the end of 2022[24]. - The company has successfully built a comprehensive medical service ecosystem covering pharmaceutical companies, retail pharmacies, healthcare providers, and patients[62]. Foreign Exchange and Financing - The group recorded a net foreign exchange loss of approximately HKD 3,150,000 due to fluctuations in the Chinese Yuan and Korean Won against the Hong Kong Dollar[29]. - The company raised HKD 49,029,000 from bank and other borrowings during the six months ended June 30, 2023, compared to HKD 10,364,000 in the same period of 2022[80]. - The net financing costs amounted to HKD 1,196,000 for the period[169]. Other Financial Metrics - The company's basic and diluted loss per share for the six months ended June 30, 2023, was HKD 0.32, compared to HKD 0.88 in the same period of 2022[111]. - Other comprehensive loss for the period, net of tax, was HKD 7,072,000, compared to HKD 17,540,000 in the previous year[112]. - The company has not made any provisions for Hong Kong profits tax due to no estimated taxable profits arising from Hong Kong during the period[177].

Financial Performance - The company reported a net loss of HKD 316,598,000 for the year, compared to a net loss of HKD 141,427,000 in the previous year[60]. - The total comprehensive loss amounted to HKD 14,340,000 for the year ended December 31, 2022, compared to HKD 15,188,000 in the previous year[26]. - The company reported a net loss of HKD 269,980,000 for the year ended December 31, 2022, compared to a loss of HKD 110,402,000 in 2021[150]. - The company’s adjusted net loss for the year was HKD 295.6 million, reflecting a 159% increase from HKD 114.3 million in the previous year[122]. - The company reported a significant increase in marketing and promotional expenses, which rose to HKD 334,317 thousand in 2022 from HKD 15,626 thousand in 2021, reflecting a substantial increase in marketing efforts[195]. - The company recorded a loss of HKD 316,598,000 for the year ended December 31, 2022, compared to a loss of HKD 141,427,000 in 2021[60]. - The company reported a net loss before tax of HKD (141,845) thousand for 2022, compared to a net loss of HKD (418) thousand in 2021, indicating a substantial increase in pre-tax losses[192]. Revenue Growth - The company's total revenue for the year ended December 31, 2022, was HKD 1,692,061,000, a significant increase from HKD 327,713,000 in 2021[54]. - Revenue from online pharmaceutical prescriptions, circulation, and marketing reached HKD 606,130,000, up from HKD 35,968,000 in the previous year, indicating a growth of approximately 1,684%[54]. - The smart health service platform generated HKD 807,511,000 in health consumption revenue, compared to HKD 22,457,000 in 2021, reflecting an increase of about 3,493%[54]. - The main revenue sources were "Yizhi Nuo" and "Mango Health," generating revenues of HKD 606 million and HKD 824 million respectively, together accounting for 85% of total revenue[132]. - The company’s revenue from external customers in China was HKD 1,564,234 thousand in 2022, a significant increase from HKD 174,905 thousand in 2021, reflecting a growth of approximately 795%[194]. Assets and Liabilities - Total assets amounted to HKD 589.2 million as of December 31, 2022, down from HKD 911.2 million the previous year[141]. - The total assets of the company were reported at HKD 589,186,000, with total liabilities of HKD 239,261,000[163]. - Total liabilities decreased to HKD 239,261,000 in 2022 from HKD 252,300,000 in 2021[152]. - The company’s total liabilities increased to HKD 252,300 thousand in 2022 from HKD 230,485 thousand in 2021, representing an increase of about 9.5%[193]. Cash Flow and Financial Position - Operating cash outflow was HKD 90,236,000 for the year ended December 31, 2022, compared to an operating cash inflow of HKD 108,695,000 in 2021[60]. - Cash and cash equivalents decreased to HKD 38.3 million from HKD 148.6 million in the previous year[141]. - The company has sufficient operating funds to meet its financial obligations for the next twelve months[60]. - The company has a total of HKD 94,182,000 in accounts payable as of December 31, 2022, compared to HKD 29,291,000 in 2021[156]. Investments and Acquisitions - The Group completed the acquisition of a 21.88% stake in Deep Sea Health Limited for RMB 20 million on August 12, 2021[23]. - The company completed the acquisition of 51% of Pingtan Xinban Clinic for a total cash consideration of RMB 40 million (approximately HKD 47.9 million)[113]. - The group issued 24,732,032 new shares to founding shareholders in August 2022 as part of the acquisition agreement[108]. Shareholder Information - The total issued and fully paid shares as of December 31, 2022, were 13,585,339,000 ordinary shares and 240,760,000 preference shares[71]. - The group issued 77,500,000 shares under the share incentive plan during the year, with 62,500,000 shares vested and issued[86]. - Basic and diluted loss per share was HKD 1.99, compared to HKD 0.82 in the previous year[134]. Strategic Focus and Future Plans - The company aims to expand its digital marketing business for pharmaceutical companies, with plans to develop SaaS services targeting these companies this year[132]. - The company is actively pursuing partnerships with major hospitals to develop smart health management services[132]. - The company has begun assessing the impact of new or revised standards, interpretations, and amendments, with management expecting no significant impact on the financial position and operating performance[90]. Impairment and Provisions - The company incurred impairment provisions of HKD 10,152,000 in 2022, up from HKD 1,707,000 in 2021[148]. - The company has incurred impairment losses on financial assets amounting to HKD 36,492,000[160]. - The impairment test for goodwill indicated no need for impairment, as reasonable changes in assumptions would not lead to impairment[22]. Market and Industry Insights - The Chinese internet healthcare market is projected to reach RMB 162.6 billion in 2023, with a compound annual growth rate of 20% from 2020 to 2023[109]. - The company’s strategic focus on internet health transformation has begun to yield results, with significant growth in core business areas[110].